Literature DB >> 11813625

Expression of insulin-like growth factor-2, c-MET, matrix metalloproteinase-7 and MUC-1 in primary lesions and lymph node metastatic lesions of gastric cancer.

H Ajisaka1, S Fushida, Y Yonemura, K Miwa.   

Abstract

BACKGROUND/AIMS: Lymph node metastases are thought to be formed as lymphatic flow, so the first metastasis is formed in the lymph node nearest the primary tumor and then further lymph node metastases are formed continuously down stream. In this study of gastric cancer, we evaluated whether IGF-2 (insulin-like growth factor-2), c-MET (hepatocyte growth factor receptor), MMP-7 (matrix metalloproteinase-7) and MUC-1, which are associated with nodal metastasis from primary tumor, are concerned with metastasis from nodal metastatic lesion to other nodes.
METHODOLOGY: Tissue specimens were obtained from 146 patients who underwent gastrectomy at the Department of Surgery II of Kanazawa University between 1989 and 1997. We evaluated the expression of IGF-2, c-MET, MMP-7 and MUC-1 in 146 primary tumors and 66 metastatic lymph nodes by immunohistological staining.
RESULTS: In primary lesions, these 4 factors had significant association with lymphatic vessel infiltration and MMP-7 and MUC-1 had significant association with nodal metastases. In nodal metastatic lesions, positive rates of MMP-7 and MUC-1 were higher than in primary lesions. Furthermore, 37 (73%) of the 51 cases with positive staining for MMP-7 in metastatic lesions in perigastric lymph nodes and 5 (33%) of the 15 cases without the staining had nodal metastases in group 2 or more, showing significant difference (P < 0.05). And 37 (76%) of the 49 cases with positive staining for MUC-1 in metastatic lesions in perigastric lymph nodes and 5 (29%) of the 17 cases without the staining had nodal metastases in group 2 or more, showing significant difference (P < 0.01).
CONCLUSIONS: MMP-7 and MUC-1 were associated with not only nodal metastasis from primary tumor but also metastasis from nodal metastatic lesion to other nodes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11813625

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.

Authors:  Y Min; Y Adachi; H Yamamoto; A Imsumran; Y Arimura; T Endo; Y Hinoda; C-T Lee; S Nadaf; D P Carbone; K Imai
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

2.  A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers.

Authors:  Yasushi Adachi; Hiroyuki Yamamoto; Hirokazu Ohashi; Takao Endo; David-P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

3.  Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers.

Authors:  Yu Wang; Yasushi Adachi; Arisa Imsumran; Hiroyuki Yamamoto; Wenhua Piao; Hua Li; Masanori Ii; Yoshiaki Arimura; Mi Young Park; Dalrae Kim; Choon-Taek Lee; David P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  J Gastroenterol       Date:  2009-11-10       Impact factor: 7.527

4.  Release of membrane-associated mucins from ocular surface epithelia.

Authors:  Timothy D Blalock; Sandra J Spurr-Michaud; Ann S Tisdale; Ilene K Gipson
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05       Impact factor: 4.799

5.  p120 and Kaiso regulate Helicobacter pylori-induced expression of matrix metalloproteinase-7.

Authors:  Seth R Ogden; Lydia E Wroblewski; Christiane Weydig; Judith Romero-Gallo; Daniel P O'Brien; Dawn A Israel; Uma S Krishna; Barbara Fingleton; Albert B Reynolds; Silja Wessler; Richard M Peek
Journal:  Mol Biol Cell       Date:  2008-07-23       Impact factor: 4.138

Review 6.  Matrix Metalloproteinases in Helicobacter pylori-Associated Gastritis and Gastric Cancer.

Authors:  Olga Sokolova; Michael Naumann
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.